Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance.

Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, Ching AK, Tong JH, Ng HK, Johnson PJ, To KF.

Int J Cancer. 2009 Feb 1;124(3):644-52. doi: 10.1002/ijc.23968.

2.

Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.

Pang E, Hu Y, Chan KY, Lai PB, Squire JA, Macgregor PF, Beheshti B, Albert M, Leung TW, Wong N.

Lab Invest. 2005 May;85(5):664-74.

3.

Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.

Chen L, Yuan YF, Li Y, Chan TH, Zheng BJ, Huang J, Guan XY.

Gut. 2011 Apr;60(4):534-43. doi: 10.1136/gut.2010.224071. Epub 2010 Nov 10.

PMID:
21068133
4.

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T.

Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042. Review.

5.

Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.

Pierceall WE, Sprott KM, Heikkinen T, Heikkila P, Alaparthi L, Aittomaki K, Al-Adhami M, Villegas-Bergazzi V, Meyer JL, Kutok JL, Bartkova J, Bartek J, Nevanlinna H, Weaver DT, Blomqvist C.

Hum Pathol. 2012 Sep;43(9):1363-75. doi: 10.1016/j.humpath.2011.08.018. Epub 2011 Dec 26.

PMID:
22204715
6.

Overexpressed nuclear BAG-1 in human hepatocellular carcinoma is associated with poor prognosis and resistance to doxorubicin.

Ni W, Chen B, Zhou G, Lu C, Xiao M, Guan C, Zhang Y, He S, Shen A, Ni R.

J Cell Biochem. 2013 Sep;114(9):2120-30. doi: 10.1002/jcb.24560.

PMID:
23553841
7.

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.

Xu YC, Zhang FC, Li JJ, Dai JQ, Liu Q, Tang L, Ma Y, Xu Q, Lin XL, Fan HB, Wang HX.

Oncol Rep. 2015 Oct;34(4):1883-94. doi: 10.3892/or.2015.4183. Epub 2015 Aug 7.

PMID:
26252353
8.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group.

Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.

9.

TOP2A amplification and overexpression in hepatocellular carcinoma tissues.

Panvichian R, Tantiwetrueangdet A, Angkathunyakul N, Leelaudomlipi S.

Biomed Res Int. 2015;2015:381602. doi: 10.1155/2015/381602. Epub 2015 Jan 28.

10.

Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.

Oncology. 2011;80(3-4):269-77. doi: 10.1159/000329038. Epub 2011 Jul 7.

PMID:
21734419
11.

Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance.

Kaplan E, Gündüz U.

Biomed Pharmacother. 2012 Feb;66(1):29-35. doi: 10.1016/j.biopha.2011.09.002. Epub 2011 Dec 28.

PMID:
22285073
12.

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI.

J Natl Cancer Inst. 2009 May 6;101(9):644-50. doi: 10.1093/jnci/djp067. Epub 2009 Apr 28.

13.

Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Eralp Y, Keskin S, Akışık E, Akışık E, İğci A, Müslümanoğlu M, Yılmaz S, Tunacı M, Çamlıca H, Tuzlalı S, Saip P, Dalay N, Özmen V, Topuz E.

Am J Clin Oncol. 2013 Jun;36(3):215-23. doi: 10.1097/COC.0b013e318243913f.

PMID:
22441341
15.

Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.

Şahin S, Işık Gönül İ, Çakır A, Seçkin S, Uluoğlu Ö.

Int J Surg Pathol. 2016 Oct;24(7):607-13. doi: 10.1177/1066896916653211. Epub 2016 Jun 9.

PMID:
27284123
16.

Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.

Park K, Han S, Gwak GH, Kim HJ, Kim J, Kim KM.

Breast Cancer Res Treat. 2006 Aug;98(3):337-42. Epub 2006 Feb 24.

PMID:
16502015
17.

Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.

Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K, Umeshita K, Matsuura N, Matsubara K, Doki Y, Mori M, Monden M.

Br J Cancer. 2009 May 19;100(10):1647-58. doi: 10.1038/sj.bjc.6605064. Epub 2009 Apr 28.

18.

FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.

Fang F, Yang L, Tao Y, Qin W.

Cancer. 2012 Jan 1;118(1):134-46. doi: 10.1002/cncr.26251. Epub 2011 Jun 28.

19.

Identification of transmembrane protein 98 as a novel chemoresistance-conferring gene in hepatocellular carcinoma.

Ng KT, Lo CM, Guo DY, Qi X, Li CX, Geng W, Liu XB, Ling CC, Ma YY, Yeung WH, Shao Y, Poon RT, Fan ST, Man K.

Mol Cancer Ther. 2014 May;13(5):1285-97. doi: 10.1158/1535-7163.MCT-13-0806. Epub 2014 Mar 7.

20.

Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.

Nygård SB, Christensen IJ, Smith DH, Nielsen SL, Jensen NF, Nielsen HJ, Vainer B, Brünner N.

Scand J Gastroenterol. 2013 Dec;48(12):1436-43. doi: 10.3109/00365521.2013.848230. Epub 2013 Oct 21.

PMID:
24138107

Supplemental Content

Support Center